Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.48 |
| ▸ | PDE4A | P27815 | 5/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.48 |
| ▸ | TPH1 | P17752 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7940494 | 0.90 | RECQL (0.43) | RECQLPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL7418284 | 0.89 | RECQL (0.47) | RECQLPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL7471407 | 0.86 | PDE4B (0.50) | RECQLPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL6571638 | 0.84 | POLB (0.50) | RECQLPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL7415564 | 0.83 | TPH1 (0.51) | RECQLPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL7937749 | 0.83 | TPH1 (0.51) | RECQLPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL7422273 | 0.82 | RECQL (0.47) | RECQLPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL7420665 | 0.82 | PDE4B (0.48) | RECQLPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL7412528 | 0.80 | TPH1 (0.47) | RECQLPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL2958828 | 0.77 | RECQL (0.60) | RECQLPDE4BPDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150119399-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2015-04-30 | — | — | US | claimed |
| EP-2804603-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | President and Fellows of Harvard College (US) | 2014-11-26 | — | — | EP | claimed |
| WO-2013106547-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-07-18 | — | — | WO | claimed |
| US-7803760-B2 | Methods of inducing ovulation | MERCK SERONO SA (CH) | 2010-09-28 | — | — | US | claimed |
| JP-4532115-B2 | — | — | 2010-08-25 | — | — | JP | claimed |
| US-20080293622-A1 | METHODS OF INDUCING OVULATION | MERCK SERONO SA (CH) | 2008-11-27 | — | — | US | claimed |
| CN-101257904-A | Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist | NYCOMED GMBH (DE) | 2008-09-03 | — | — | CN | claimed |
| EP-1849468-A2 | Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist | Nycomed GmbH (DE) | 2007-10-31 | — | — | EP | claimed |
| US-20060079540-A1 | Pde4 and pde3/4 inhibitors for use in the treatment of cachexia | ALTANA PHARMA AG (DE) | 2006-04-13 | — | — | US | claimed |
| US-6953774-B2 | Methods of inducing ovulation | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2005-10-11 | — | — | US | claimed |
| WO-2003074055-A1 | PHARMACEUTICAL COMPOSITION OF A PDE4 OR A PDE3/4 INHIBITOR AND A HISTAMINE RECEPTOR ANTAGONIST | ALTANA PHARMA AG (DE) | 2003-09-12 | — | — | WO | claimed |
| WO-2003051344-A1 | METHODS OF INDUCING OVULATION_USING A NON-POLYPEPTIDE CAMP LEVEL MODULATOR | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-06-26 | — | — | WO | claimed |
| US-20030092706-A1 | Combination | NYCOMED GMBH (DE) | 2003-05-15 | — | — | US | claimed |
| WO-2003024488-A2 | COMBINATION OF A PDE INHIBITOR AND A LEUKOTRIENE RECEPTOR ANTAGONIST | ALTANA PHARMA AG (DE) | 2003-03-27 | — | — | WO | claimed |
| US-20020103106-A1 | Methods of inducing ovulation | MERCK SERONO SA (CH) | 2002-08-01 | — | — | US | claimed |
| EP-0766676-B1 | COMPOUNDS FOR INHIBITING PHOSPHODIESTERASE IV | EURO CELTIQUE SA (LU) | 2002-05-22 | — | — | EP | claimed |
| US-5922751-A | BRONCHODILATOR AND ANTIINFLAMMATORY AGENT WITHOUT UNDESIRABLE CARDIOVASCULAR STIMULATION CAUSED BY PHOSPHODIESTERASE III INHIBITOR | EURO-CELTIQUE, S.A. (LU) | 1999-07-13 | — | — | US | claimed |
| EP-0766676-A4 | COMPOUNDS FOR AND METHOD OF INHIBITING PHOSPHODIESTERASE IV | EURO CELTIQUE SA (LU) | 1998-07-08 | — | — | EP | claimed |
| EP-0766676-A1 | COMPOUNDS FOR AND METHOD OF INHIBITING PHOSPHODIESTERASE IV | Euroceltique S.A. (LU) | 1997-04-09 | — | — | EP | claimed |
| WO-1996000218-A1 | COMPOUNDS FOR AND METHOD OF INHIBITING PHOSPHODIESTERASE IV | EURO-CELTIQUE, S.A. (LU) | 1996-01-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079540-A1 | Pde4 and pde3/4 inhibitors for use in the treatment of cachexia | PDE4A, PDE12, PDE4B | RECQL 2290/4885PDE4B 3/4885PDE4A 1/4885 |
| US-20150119399-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | IAPP, GPR119, PCNA | RECQL 299/4885PDE4B 1204/4885PDE4A 1173/4885 |
| US-20020103106-A1 | Methods of inducing ovulation | PDE4A, PDE4B, PDE4C | RECQL 2376/4885PDE4B 2/4885PDE4A 1/4885 |
| US-20080293622-A1 | METHODS OF INDUCING OVULATION | PDE4A, PDE4B, PDE4C | RECQL 2342/4885PDE4B 2/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.